Growth Hormone And Nutritional Status

Scacchi, Massimo; Pincelli, Angela Ida; Cavagnini, Francesco

doi:10.1007/978-1-4615-1579-1_15

Cited by 1 publication

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 GH secretion is significantly decreased in obese patients compared to healthy individuals. 13 A cross-sectional study divided 168 obese children and adolescents into two groups: NAFLD and non-NAFLD. 14 NAFLD patients showed significantly lower IGF1 standard deviation score (SDS), which was calculated according to age and sex, 15 compared to non-NAFLD individuals.…”

Section: Gh Obesity and Nafldmentioning

confidence: 99%

Growth Hormone Signaling in Liver Diseases: Therapeutic Potentials and Controversies

2023

View full text Add to dashboard Cite

Growth hormone (GH) and downstream insulin-like growth factor 1 (IGF1) signaling mediate growth and metabolism. GH deficiency causes short stature or dwarfism, and excess GH causes acromegaly. Although the association of GH/IGF1 signaling with liver diseases has been suggested previously, current studies are controversial and the functional roles of GH/IGF1 signaling are still undefined. GH supplementation therapy showed promising therapeutic effects in some patients, such as non-alcoholic fatty liver disease, but inhibition of GH signaling may be beneficial for other liver diseases, such as hepatocellular carcinoma. The functional roles of GH/IGF1 signaling and the effects of agonists/antagonists targeting this signaling may differ depending on the liver injury or animal models. This review summarizes current controversial studies of GH/IGF1 signaling in liver diseases and discusses therapeutic potentials of GH therapy.

show abstract

Section: Gh Obesity and Nafldmentioning

confidence: 99%